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Study on Pegylation of Therapuetic Enzyme Uricase
And Its Physio-Chemical Properties For Improving Its
Pharmaceutical Characteristics

Pooja Nanda & P.E.Jagdeesh Babu
Department of Chemical Engineering, National Institute of Technology Karnataka, Srinivasnagar, Surathkal,
Karnataka- 575 025, India

Abstract - Uricase (urate oxidase EC 1.7.3.3, UC) catalyses the oxidation of uric acid, a final product of purine catabolism to
allantoin. In the present work, Uricase is bioconjugated using PEG (Polyethylene glycol) as a chemical tool for linking for obtaining
conjugates with better and desirable pharmaceutical properties. Uricase from Bacillus fastidisous (Uc) was modified through
PEGylation considering various concentrations of linear polyethyleneglycol-8KDa (PEG-8K). The Uc-PEG 8K conjugates, formed
by conjugating Uc and PEG-8K in the ratio of 1:15 retained 87.5% of the initial uricolytic activity, and were highly stable at pH 6.0,
which is quiet close to physiological pH and at a temperature of 16°C.
Keywords - Uricase, Gout, PEGylation, Physiochemical Stability.

I.

enzyme. However, these treatments can sometimes
prove to be inefficient, leading to serious clinical
complications [7], [8]. Administration of uricase has
proved to be a good alternative to treat gout, but uricase
from microorganisms and animals in its native form is
highly antigenic, and the chronicle treatment with
uricase results in allergic reactions and anaphylactic
shock [5]. Uricase administered externally, gets
inactivated by proteolysis and hence exhibits a very
short plasma half life. This problem can be overcome by
conjugation of uricase with PEG (Polyethylene glycol).

INTRODUCTION

Uricase (EC 1.7.3.3, UC) is a therapeutic enzyme
belonging to the class of the oxidoreductases, which
catalyses the oxidation of uric acid, producing allantoin
and acting in the purine degradation pathway. Uricase is
useful for enzymatic determination of uric acid in
biological fluids for clinical analysis [1]. Uricase can be
also used as a protein drug to reduce toxic urate
accumulation [2]. Immobilized uricase can be used as a
uric acid biosensor [3]. Uricase is also used as an
additive in commercial formulations of hair coloring
agents [4].

Recently studies performed showed that
PEGylation is a well succeeded methodology, used to
widen the therapeutic and biotechnological uses of
proteins. [9], [10], [11], [12], [13]. PEGylation increases
the overall size and molecular weight of the proteinPEG conjugate and hence increases the plasma half life
by avoiding ultrafiltration through kidneys. It brings
about charge modification and epitope shielding and
thus
diminishes
immunogenicity
[14].
The
administration of the PEGylated conjugate facilitates
longer dosage intervals and reduces risk of adverse
immunological reactions. Uricases from Candida utilis
[15], [16], [17], [18], [19], [20], Arthrobacter
protoformiae [21], Bacillus fastidiosus [7], [22] and
from mammals [16], [23] have been PEGylated.
Presently the PEGylated forms of uricase enzyme
commercially available are PEGsitacase (Uricase-PEG
20) [EnzymeRx], KRYSTEXXA™ (Pegloticase),

Uricase is produced as a truncated, 10 amino acids
long, inactive protein fragment in humans and apes, due
to a nonsense codon inserted into its gene during the
early primate evolution [5]. Due to its absence humans,
the plasma concentration of uric acid is rather high [6],
and an abnormal raise of this metabolite can promote
renal failure and contribute to the development of
disease known as gout. The normal serum urate level of
uric acid is between 0.13 and 0.46 mM (2.18– 7.7 mg
dl–1). If the blood serum concentration of uric acid go
beyond these particular levels due to tumor lysis
syndrome and dietary reasons then, uric acid tends to
precipitate and develop into inflammatory and painful
gouty arthritis. The treatment of hyperuricemia has been
performed with drugs that induce forced diuresis,
urinary alcalinization and ones which decrease amount
of uric acid synthesized by inhibiting xanthine oxidase
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Puricase® [Savient Pharmaceuticals], PEG40-Uricase
[Mountain View Pharmaceuticals].

reaction mixture volumes. The blank and the test
solutions were incubated at 25°C for ten minutes, after
which the decrease in the uric acid concentration was
measured with the aid of a UV-Visible
spectrophotometer at 293nm. The difference in
absorbance of the test and blank is equivalent to the
decrease in uric acid concentration during the enzyme
reaction. One unit of enzyme activity was defined as the
amount of uricase required to convert 1 µmol of uric
acid into allantoin per minute at 25°C and at pH 9.0,
considering milli molar extinction co-efficient of uric
acid at 293nm as 12.6 mM-1cm-1. The activity of the
enzyme before and after bioconjugation was determined
using this method.

There are only a few reports of conjugation of
Uricase from Bacillus fastidiosus to PEG molecules.
Uricase from Bacillus fastidiosus has been conjugated to
linear PEG-5 kDa, branched PEG-10 kDa, Poly (Nacryloylmorpholine) -6 KDa by Schiavon et al in 2000
[7] and with monomethoxy-polyethylene glycol
modified with NHS ester- 5 kDa by Chun et al in 2010
[22]. The present work is a new report on conjugation of
Uricase from Bacillus fastidiosus with a linear molecule
of Polyethylene glycol 8 kDa. Uricase and PEG were
conjugated in different concentration ratios and their
residual activities were found after conjugation, the
stability at various pH and temperature conditions was
also evaluated.

d) Effect of pH on the stability of unmodified uricase
and the bioconjugate

Uricase (Uc) from Bacillus fastidiosus (Molecular
weight: 35 kDa and Enzymatic activity: 9 U/mg) and
linear Polyethylene glycol (PEG-8K) were obtained
from Sigma Aldrich Chemical Company (Germany).
SDS-PAGE Kit and Reagents were bought from
Chromous Biotech (India). Protein Marker (14 kDa-110
kDa) was also obtained from Chromous Biotech (India).

The stability of the unmodified uricase and the
bioconjugates was tested at different pH values by
maintaining them in the following buffers solutions for
an hour: for pH 6-7 sodium phosphate buffer, for pH 89, Borate buffer and for pH 10 Tris-HCl buffer. The
enzymatic activities of the conjugates were determined
after one hour of incubation. The pH at which the
unmodified uricase showed the highest activity, was
considered to possess 100% residual activity, and the
activities at other pH values were evaluated with respect
to the highest value of residual activity.

B. Methods:

e)

II. MATERIALS AND METHODS
A.

Materials:

a) Preparation of Uc-PEG 8K conjugates

Unmodified uricase and the bioconjugates were
incubated at different temperatures which are as follows
4°C, 16°C, 32°C, 80°C, 100°C for an hour in 100mM
sodium borate buffer pH 9. At the end of this
incubation, the enzymatic activities of unmodified
uricase and the bioconjugates was determined as
described in the uricase enzyme assay procedure.

Commercially obtained pure unmodified Uricase
from Bacillus fastidiosus (1 mg/mL) was allowed to
react with linear PEG-8K in the concentration ratios of
1:15, 1:20, 1:25 and 1:30 of Uc to PEG-8K, in 100mM
sodium borate buffer solution having pH 9.0, as the
reaction medium in a final volume of 1 mL. These
components of the mixtures were allowed to react at
30°C with slight agitation for 2 hours.
b)

SDS-PAGE analysis
PEGylation

for

the

confimation

III. RESULTS AND DISCUSSIONS

of

A. Modification of Uricase by Bioconjugation:
Aliquots of commercially obtained uricase were
subjected to bioconjugation reaction with linear PEG8K used, as described in the method above and the
enzyme activities of the conjugates were calculated and
compared to that of the unmodified uricase, by
considering their activity relative to that of the
unmodified uricase whose activity is considered as
100%) as shown in Table 1.

Sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) was performed according
to the method described by Laemmli (1970) [24] for the
determination of molecular weights of the conjugates
formed. Staining and detection of protein bands was
done using Coomassie blue stain and later destained.
c)

Effect of temperature on stability of unmodified
uricase and the bioconjugate

Uricase enzyme assay and protein measurement

The enzymatic assay for uricase was carried out by
the method described by Mahler et al (1955) [25]. To 3
mL of 20 mM boric acid buffer of pH 9.0, 75 µL of 3.57
mM uric acid solution and 20 µL of enzyme solution
were added at 25°C. For the blank, 20 µL of buffer was
added, instead of the enzyme solution to equate the

Uc-PEG 8K conjugates retained 87.5% of the initial
uricolytic activity when Uc and PEG-8K were reacted in
a concentration ratio of 1:15. In previous studies of
bioconjugation of a recombinant intracellular uricase
from Bacillus fastidiosus ATCC 29604, Chun et al [19]
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for stability testing based on the possession of maximum
residual activities among all the other bioconjugates
formed. The choosen bioconjugates were subjected to
further studies of stability in various buffers of different
pH values, in order to find an appropriate buffer which
can be used for storage and maintenance of the
bioconjugates for a prolonged time. Uc-PEG 8K
bioconjugate was stable at pH 6.0 as indicated in Fig 2.

used modified NHS ester of the polymer and found out
that the complex of mPEG (5 KDa) and uricase showed
a residual activity of 65%. In another study, by Schiavon
et al [7] on bioconjugation of uricase from Bacillus
fastidiosus with linear PEG (Mol Wt 5 kDa), PEG (Mol
wt 10 kDa) and poly (N-acryloylmorpholine) (PAcM)
(Mol Wt 6 kDa), the residual activities were 40%, 76%
and 24% respectively. From the data obtained through
our present experimental results, retention of high
residual activity, as high as 87.5% even after
conjugation is very significant, as possession of high
uricolytic activity is desired for an enzyme drug to be
suited for administration.
Table 1. Residual activities after conjugation of Uc with
PEG-8K in different concentration ratios
Uc:PEG8K ratio
Unmodified
Uricase
1:15

Residual
Activity (%)
100

Residual Activity
(U/mg)
9.000

87.8

7.902

1:20

18.17

1.635

1:25

37.858

3.407

1:30

63.684

5.731

Figure 2. Stability of Unmodified uricase and Uc:PEG8K at various pH values
In previous studies, Chun et al [19] observed that,
the unmodified Bacillus fastidiosus ATCC 29604
uricase, had an optimum pH slightly below 9.2, which
was not altered by modification with NHS ester of
mPEG 5K or mPEG 350.

B) Visualization of Bioconjugates on SDS-PAGE gel
and Molecular weight Determination
In the present work, results obtained from SDSPAGE indicated that there is an increase in molecular
weight of the bioconjugates formed, in comparison to
the unmodified uricase enzyme, which is evident by
visualizing the position of the protein bands formed on
SDS-PAGE gels as shown in Fig 1.

D. Stability of native and modified uricase at various
temperatures
In the present work, aliquots of bioconjugates formed in
the ratio of 1:15 of Uc:PEG-8K was choosen for
stability testing based on the possession of maximum
residual activities among all the other bioconjugates
formed. In this trial, aliquots of bioconjugates formed,
Uc:PEG-8K (in the concentration ratio of 1:15) were
subjected to further studies of stability at various
temperatures ie: 4°C, 16°C, 32°C, 80°C, 100°C, to
investigate the temperature at which the conjugates
remain the most stable. Uc-PEG 8K conjugates were
most stable at 16 °C as indicated in Fig 3. In previous
studies, Chun et al [19] observed that the unmodified
uricase had an optimum reaction temperature below
25°C, and modification with the NHS esters of mPEG
5K and mPEG 350 with uricase, did not bring about any
change in the optimum reaction temperature. But at
40°C in sodium borate buffer of pH 9.2, the unmodified
uricase showed a thermo-inactivation half life of about
40 hours. Modification with NHS ester of acetate had no
effect on its thermostability, while modification by
mPEG350 slightly enhanced its thermostability, and
modification by mPEG5K increased its thermo-

Figure 1. SDS-PAGE of Uricase after bioconjugation
with PEG-8K. Lane 1: protein marker, Lane 2:
unmodified uricase (35 KDa), Lane 3, 4, 5, 6:
Bioconjugated complexes in various ratios mentioned
earlier.
C) Stability of native and modified uricase at various pH
In the present work, aliquots of bioconjugates
formed in the ratio of 1:15 of Uc:PEG 8K was choosen
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inactivation half –life to over 85 hours at 40°C in
sodium borate buffer at pH of 9.2.

Figure 3. Stability of Unmodified uricase and Uc:PEG
8K at various temperature values
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IV. CONCLUSION
The experimental results obtained by this work
indicated an increase in the molecular weight of the
conjugate in comparison to that of the unmodified
uricase, indicating formation of Uc-PEG 8K conjugates,
which were highly stable at pH 6.0, which is quiet close
to the physiological pH, and at temperature of 16°C.
This conjugate can be further characterized and tested
for its pharmacodynamic and pharmacokinetic
properties through clinical trials for its therapeutic
usage.
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